Portage Biotech Inc. (NASDAQ:ALP – Free Report) – HC Wainwright issued their Q1 2027 EPS estimates for Portage Biotech in a research report issued on Monday, August 17th. HC Wainwright analyst M. Colonnese anticipates that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Neutral” rating and a $0.25 price target on the stock. HC Wainwright also issued estimates for Portage Biotech’s Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.28) EPS.
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Portage Biotech in a research note on Friday, July 24th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $0.25.
Portage Biotech Stock Performance
Shares of ALP opened at $0.16 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.31 and a quick ratio of 0.31. The firm has a market cap of $3.82 million, a PE ratio of -0.02 and a beta of 0.61. Portage Biotech has a 1 year low of $0.15 and a 1 year high of $13.80. The stock’s fifty day moving average price is $0.28 and its two-hundred day moving average price is $0.35.
Portage Biotech (NASDAQ:ALP – Get Free Report) last released its earnings results on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The company had revenue of $0.05 million during the quarter.
Key Headlines Impacting Portage Biotech
Here are the key news stories impacting Portage Biotech this week:
- Positive Sentiment: HC Wainwright assigned Portage Biotech a $0.25 price target, materially above the roughly $0.16 reference price, implying substantial upside if the target is achieved. The initiation of coverage may also improve investor awareness of the company. HC Wainwright Initiates Coverage on Portage Biotech
- Neutral Sentiment: The firm’s official rating is Neutral, indicating that HC Wainwright does not currently see a strong enough catalyst to recommend buying or selling the shares despite the higher price target. Portage Biotech analyst coverage
- Negative Sentiment: HC Wainwright forecasts ongoing losses, including EPS of negative $0.10 in Q1 2027, negative $0.07 in Q2 and Q3, and negative $0.06 in Q4, for a full-year 2027 loss of negative $0.28 per share. For 2028, it projects negative $0.04 EPS in each quarter and a full-year loss of negative $0.17.
- Negative Sentiment: Portage Biotech has a very small market capitalization of approximately $3.8 million and weak liquidity metrics, including a quick ratio and current ratio of 0.31. Its shares also remain near the one-year low, highlighting substantial volatility and financing risk.
Portage Biotech Company Profile
Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.
Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.
Featured Articles
- Five stocks we like better than Portage Biotech
- Amazon Plugs $18B Into the Southern Power Grid
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
